Trade TCRX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
TScan Therapeutics, Inc. (TCRX) is trading at US$0.24, up 13.63% today as of Oct 15, 16:00 EDT. The company has a market capitalisation of US$52.83M. Over the past 52 weeks, TCRX has traded between US$0.20 and US$2.57. On Syfe you can trade TCRX with $0 commission and add it to your watchlist.
| Previous close | US$0.21 |
|---|---|
| Market cap | US$52.83M |
| 52-week range | US$0.20 – US$2.57 |
| Volume | 877.6K |
| Exchange | US |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.
Year: 2021
--Needham Downgrades TScan Therapeutics to Hold From Buy
Sep 2, 6:48 PM · MT Newswires
--Wedbush Downgrades TScan Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $5
Sep 2, 2:41 PM · MT Newswires
TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment
Jun 22, 12:31 PM · MT Newswires
TScan Therapeutics, Inc. (TCRX) stock is trading at US$0.24, +13.63% from the previous close of US$0.21.
The market cap for TScan Therapeutics, Inc. (TCRX) stock is approximately US$52.83M.
The 52-week high for TScan Therapeutics, Inc. (TCRX) stock is US$2.57.
The 52-week low for TScan Therapeutics, Inc. (TCRX) stock is US$0.20.
TScan Therapeutics, Inc. (TCRX) does not currently pay a dividend.
Stay on top of TCRX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
